COMBINATION THERAPY FOR CHRONIC RECURRENT VERTEBROGENIC PAIN SYNDROME


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Due to its high analgesic effect, combination therapy for chronic musculoskeletal pain syndromes with the nonsteroidal anti-inflammatory drug (NSAID) Mesipol (Meloxicam) with the central myorelaxant Baclosan (Baclofen) can more promptly achieve significant analgesia and reduce the duration of medicamentous therapy and a risk of NSAID-associated side effects.

Full Text

Restricted Access

About the authors

E. Solovyeva

Russian National Research Medical University

Email: ellasolovieva@yandex.ru
Professor, MD

A. Ivanokov

Russian National Research Medical University

MD

A. Manevsky

Russian National Research Medical University

MD

References

  1. Atkinson J. Chronic back pain: searching for causes and cures // J. Rheumatol. - 2004; 31: 2323-5.
  2. Черненко О.А. Клинические и МР-томографические характеристики вертеброневрологических нарушений в различных возрастных группах. -Автореф. дис. ... канд. мед. наук. - 1996.
  3. Алексеев В.В. Диагностика и лечение болей в пояснице, вызванных компрессионной радикулопатией // Справ. поликлинич. врача. - 2002; 4: 23-30.
  4. Андреев В.В. О нейрохимических механизмах болеутоляющего действия ГАМК-позитивных препаратов // Нейропсихофармакология болеутоляющих средств. - Л.: 1986; с. 75-86.
  5. Slonimski M., Abram S., Zuniga R. Intrathecal baclofen in pain management // Reg. Anesth. Pain. Med. - 2004; 29 (3): 269-76.
  6. Насонов Е.Л. Применение нестероидных противовоспалительных препаратов: терапевтические перспективы // РМЖ. - 2002; 10 (4): 206-12.
  7. Caldwell B., Aldington S., Shirtcliffe P. et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis // J. R. Soc. Med. - 2006; 99: 132-40.
  8. McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase // JAMA. - 2006; 13 (296): 1-12.
  9. Doc. Ref. EMEA/413136. - 2006.
  10. Euller-Ziegler L.,Velicitat P., Bluhmki E. et al. Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration // Inflamm. Res. - 2001; 50 (1): 5-9.
  11. Zeidler H., Kaltwasser J., Leonard J. et al. Prescription and Tolerability of Meloxicam in Day-to-Day Practice: Postmarketing Observational Cohort Study of 13 307 Patients.
  12. Davies N., Skjodt N. Clinical pharmacokinetics of meloxicam: a cyclooxygenase-2 preferential non-steroidal anti-inflammatory drug // Clin. Pharmacokinet. - 1999; 36: 115-26.
  13. Цветкова Е.С., Панасюк Е.Ю., Иониченок Н.Г. и др. Перспективы применения ингибиторов циклооксигеназы-2 при остеоартрозе // Consilium Medicum. - 2004; 6 (2): 100-5.
  14. Dequeker J., Hawkey С., Kahan A. et al. Improvement in gastrointestinal tolerability on the selective cyclooxygenase (COX)-2 inhibitor meloxicam, compared with piroxicam: results of the safety and Efficacy Large scale Evalution of COX inhibiting Therapies (SELECT) trial in osteoarthritis // Br. J. Rheaumatol. - 1998; 37: 946-51.
  15. Hawkey С., Kahan A., Steinbruck K. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large Scale International Study Safety Assessment // Br. J. Rheaumatol. - 1988; 37: 937-45.
  16. Singh G., Triadafilopoulos G. Meloxicam has a low risk of serious gastrointestinal complication: pooled analysis of 27039 patients: the results of the IMPROVE trial // EULAR Congress, Prague. - 2001.
  17. Combe B., Velicitat P., Garson N. et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients // Inflamm. Res. - 2001; 50 (Suppl. 1): 10-6.
  18. Vidal L., Kneer W., Baturone M. et al. Meloxicam in acute episodes of soft-tissue rheumatism of the shoulder // Inflam. Res. - 2001; 50 (Suppl. 1): 24-9.
  19. Цветкова Е.С. Эффективность и переносимость ступенчатой терапии мовалисом (мелоксикамом) при ревматических заболеваниях // Тер. арх. -2004; 12: 78-80.
  20. Алексеев В.В. Применение мелоксикама в лечении люмбоишалгического синдрома // РМЖ. - 2003; 7 (11): 416-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies